High-dose atorvastatin was superior to standard-dose pravastatin for reducing death or major cardiovascular events in acute coronary syndromes

Hillegass, William B.; Alam, Golam K.
September 2004
ACP Journal Club;Sep/Oct2004, Vol. 141 Issue 2, p33
Academic Journal
This article focuses on alternate treatment of patients with Acute Coronary Syndrome (ACS). Researchers investigated that a standard-dose of pravastatin is noninferior to high-dose atorvastatin for reducing death or major cardiovascular events. 4162 patients (mean age 58 y, 78% men) in stable condition who were hospitalized for an ACS (acute myocardial infarction or high-risk unstable angina) in the previous 10 days, enrolled after a percutaneous revascularization procedure (if planned), and a total cholesterol level≤ 6.21 mmol/L (240 mg/dL) taken within the first 24 hours, or< 6 months after the onset of the ACS. In patients with a recent acute coronary syndrome, standard dose pravastatin was inferior to high-dose atorvastatin for reducing death or major cardiovascular events.


Related Articles

  • Meeting reporter.  // Patient Care for the Nurse Practitioner;Jan2006, Vol. 9 Issue 1, p8 

    The article offers news briefs related to medicine. Researchers at the American Heart Association's recent scientific sessions reported that, Cyclooxygenase-2 inhibitors or other NSAID use after a heart attack, especially in high dosages, increases the risk of death. Diet and low-dose...

  • Monitoring Cholesterol Levels: Measurement Error or True Change? Glasziou, Paul P.; Irwig, Les; Heritier, Stephane; Simes, R. John; Tonkin, Andrew // Annals of Internal Medicine;5/6/2008, Vol. 148 Issue 9, p656 

    Background: Cholesterol level monitoring is a common clinical activity, but the optimal monitoring interval is unknown and practice varies. Objective: To estimate, in patients receiving cholesterol-lowering medication, the variation in initial response to treatment, the long-term drift from...

  • Lipid-lowering therapy in patients with peripheral arterial disease. Collins, P.; Brittenden, J. // Vascular Medicine;2004, Vol. 9 Issue 4, p303 

    The article presents information on the impact of lipid-lowering therapy in patients with peripheral arterial disease. It states that epidemiological, post mortem and angiographic studies have consistently shown a strong positive correlation between plasma total cholesterol and the incidence of...

  • Study: The Higher the Co-Pay, the Lower the Chance That Heart Patients Stay on Cholesterol-Lowering Drugs; Even Among Those Who Need Them Most, Statin Prescriptions Go Unfilled.  // Ascribe Newswire: Medicine;6/14/2004, p77 

    Tens of millions of people in the U.S. take cholesterol-lowering drugs every day to keep their blood vessels clear and reduce their risk of heart attacks and other cardiovascular problems. A new study finds that nearly half of patients who have a prescription for any of the cholesterol-fighting...

  • Statin Therapy for Native and Peri-Interventional Coronary Heart Disease. Smith, D. A.; Galin, I. // Current Molecular Medicine;Aug2006, Vol. 6 Issue 5, p589 

    Atherosclerosis is a slow, complex process involving many different cell types and their interactions producing excessive oxidant stress, increased inflammation, abnormal endotheliumdependent vasodilation, and localized increases in thrombogenic and decreases in fibrinolytic factors. Numerous...

  • Statin Therapy and the Outcomes during Hospitalization for Acute Coronary Syndromes.  // Annals of Internal Medicine;6/1/2004, Vol. 140 Issue 11, p29 

    This article presents information on statin therapy and the outcomes during hospitalization for acute coronary syndromes. Acute coronary syndromes involve blockages in blood flow to heart muscle. If the blockage lasts long enough, an area of heart muscle dies, a condition commonly known as a...

  • High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Suk Min Seo; Eun-Ho Choo; Yoon-Seok Koh; Mahn Won Park; Dong II Shin; Yoon Seok Choi; Hun-Jun Park; Dong Bin Kim; Sung Ho Her; Jong Min Lee; Chul Soo Park; Pum-Joon Kim; Keon Woong Moon; Kiyuk Chang; Hee Yeol Kim; Ki Dong Yoo; Doo Soo Jeon; Wook Sung Chung; Yong Gyu Park; Ki-Bae Seung // Heart;Dec2011, Vol. 97 Issue 23, p1943 

    Background: A low level of high-density lipoprotein cholesterol (HDL-C) is strongly associated with cardiovascular events. However, the significance of HDLC after statin therapy on the outcome of patients who have undergone percutaneous coronary intervention (PCI) with drug eluting stents (DES)...

  • Should he have a statin? Gadsby, Roger // Update;May2006, Vol. 72 Issue 5, p101 

    This article focuses on the benefits and safety of statins in older patients. Evidence demonstrating the benefits and safety of statins in patients over 80 is sparse. Several clinical trials have demonstrated the efficacy of statins for lowering cholesterol levels and reducing the risk of...

  • Treating average cholesterol levels in patients with coronary heart disease. Lindbloom, Erik J. // Journal of Family Practice;Feb1999, Vol. 48 Issue 2, p94 

    The article cites a research study that investigates whether reduction of average cholesterol levels with pravastatin in patients with coronary heart disease (CHD) can reduce mortality and cardiovascular events. This multicenter trial recruited patients aged 31 to 75 years in Australia and New...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics